ESC 365 - Soluble urokinase-type plasminogen activator receptor (suPAR) is associated with risk for thromboembolic complications and mortality in patients with COVID-19

ESC Premium Access

Soluble urokinase-type plasminogen activator receptor (suPAR) is associated with risk for thromboembolic complications and mortality in patients with COVID-19

Session: COVID-19 and percutaneous intervention

Topic: Epidemiology, Prognosis, Outcome

Speaker: Doctor S. Luo (Chicago, US)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Doctor Shengyuan Luo

Rush University Medical Center, Chicago (United States of America)

0 follower

3 more presentations in this session

Assessment of vascular endothelial function in COVID-19 patients

Speaker: Doctor H. Mejia Renteria (Madrid, ES)

Impact of COVID-19 lockdowns on STEMI percutaneous interventions

Speaker: Doctor V. Zlochiver (Milwaukee, US)

Stroke mechanisms associated with coronavirus disease (COVID-19)

Speaker: Professor M. Kruchinina (Novosibirsk, RU)

Access the full session

COVID-19 and percutaneous intervention

Speakers: Doctor S. Luo, Doctor H. Mejia Renteria, Doctor V. Zlochiver, Professor M. Kruchinina

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources